HC Wainwright reiterated their buy rating on shares of ASLAN Pharmaceuticals (NASDAQ:ASLN – Free Report) in a report released on Friday, Benzinga reports. The brokerage currently has a $9.00 price target on the stock. Separately, Piper Sandler reaffirmed an overweight rating and issued a $10.00 price target (down previously from $15.00) on shares of ASLAN […]
ASLAN Pharmaceuticals Limited (NASDAQ:ASLN – Get Free Report) was the recipient of a large decline in short interest in the month of March. As of March 31st, there was short interest totalling 116,800 shares, a decline of 59.8% from the March 15th total of 290,500 shares. Currently, 0.7% of the shares of the company are […]
ASLAN Pharmaceuticals (NASDAQ: ASLN) shares descend Friday, as the San Mateo, Calif.-based firm, clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial .
ASLAN Pharmaceuticals Limited (NASDAQ:ASLN – Get Free Report) was the target of a significant drop in short interest in the month of March. As of March 31st, there was short interest totalling 116,800 shares, a drop of 59.8% from the March 15th total of 290,500 shares. Currently, 0.7% of the shares of the company are […]